Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merete B Long

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
ERJ Open Research|March 12, 2024
SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trialMerete B Long, Hani Abo-Leyah, Yan Hui Giam, et al.
ERJ Open Research|March 11, 2026
Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research networkMerete B Long, Jaa Ming New, Jamie Stobo, et al.
Thorax|February 14, 2026
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE studyJennifer Pollock, Jeffrey T J Huang, Morven Shuttleworth, et al.
The European Respiratory Journal|May 21, 2026
Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?James D Chalmers, Charles S Haworth, Patrick Flume, et al.
The European Respiratory Journal|December 14, 2023
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infectionMerete B Long, Andrew J M Howden, Holly R Keir, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2025
Upper-Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE StudyHayoung Choi, Hollian Richardson, Chandani Hennayake, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2026
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registryOriol Sibila, Lidia Perea, Pierre Regis Burgel, et al.
The European Respiratory Journal|September 28, 2025
European Respiratory Society clinical practice guideline for the management of adult bronchiectasisJames D Chalmers, Charles S Haworth, Patrick Flume, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2025
Investigating the impact of dipeptidyl peptidase-1 inhibition in humans using multi-omicsMerete B Long, Amy Gilmour, Rebecca C Hull, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
ERJ Open Research|March 12, 2024
SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trialMerete B Long, Hani Abo-Leyah, Yan Hui Giam, et al.
ERJ Open Research|March 11, 2026
Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research networkMerete B Long, Jaa Ming New, Jamie Stobo, et al.
Thorax|February 14, 2026
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE studyJennifer Pollock, Jeffrey T J Huang, Morven Shuttleworth, et al.
The European Respiratory Journal|May 21, 2026
Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?James D Chalmers, Charles S Haworth, Patrick Flume, et al.
The European Respiratory Journal|December 14, 2023
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infectionMerete B Long, Andrew J M Howden, Holly R Keir, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2025
Upper-Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE StudyHayoung Choi, Hollian Richardson, Chandani Hennayake, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
American Journal of Respiratory and Critical Care Medicine|June 25, 2026
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registryOriol Sibila, Lidia Perea, Pierre Regis Burgel, et al.
The European Respiratory Journal|September 28, 2025
European Respiratory Society clinical practice guideline for the management of adult bronchiectasisJames D Chalmers, Charles S Haworth, Patrick Flume, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2025
Investigating the impact of dipeptidyl peptidase-1 inhibition in humans using multi-omicsMerete B Long, Amy Gilmour, Rebecca C Hull, et al.
Pageof 4